New hope for KRAS G12C lung cancer: targeted combo therapy enters phase 2 trial

NCT ID NCT07294261

Not yet recruiting Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Dec 29, 2025 · Last updated Apr 29, 2026 · Updated 25 times

Summary

This study tests a new drug combination (goselasib plus other treatments) as a first-line therapy for people with a specific genetic mutation (KRAS G12C) in advanced or metastatic non-small cell lung cancer. About 69 adults who have not had prior treatment for their advanced cancer will take part. The goal is to see if the combination shrinks tumors and delays disease progression, while monitoring safety.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCAL ADVANCED OR METASTATIC NSCLC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Sun Yat-sen University

Guangzhou, Guangdong, 510000, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

LOCAL ADVANCED OR METASTATIC NSCLC